Ann: HER-Vaxx superior to Herceptin in tumour model, page-2

HER-Vaxx Demonstrates Significant Inhibition of Tumour Cell Growth vs Herceptin®

• Research shows promising inhibition of tumour cells by HER-Vaxx when compared with Herceptin® in tumour model
• HER-Vaxx re-formulation shows a more rapid and greater anti-cancer antibody production
• Clinical program on track Melbourne,
Australia, 22 May 2015: Imugene Limited (ASX:IMU),
a clinical stage immunooncology company developing HER-2 positive gastric and breast cancer immunotherapies, provides a progress update as per attached.

Charles Walker, Managing Director of Imugene, said, “With improvements to the formulation of HER-Vaxx, and empirical-based optimism that HER-Vaxx appears superior to Herceptin, we are rapidly finalising plans to trial our novel HER-Vaxx immunotherapeutic vaccine in patients with gastric cancer later this year.
We are developing HER-Vaxx to generate a fast and strong stimulation of patients’ immune systems to produce natural antibodies superior to Herceptin.
We are pleased to report that this Phase 1b/2 clinical program remains on track.”
This update includes key preclinical data in a tumour model where HER-Vaxx shows an advantage over Herceptin as well as other company progress.